The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Long-term follow-up of adjuvant DC-CIK following high-dose IFN versus high-dose IFN or anti-PD1 for resected acral/cutaneous melanoma.
 
Lu Si
Honoraria - MSD; Novartis; Shanghai Junshi Biosciences; Shanghai Kezhou Pharmaceutical
 
Lili Mao
Honoraria - MSD; Novartis; Shanghai Junshi BioSciences
Research Funding - MSD
 
Caili Li
No Relationships to Disclose
 
Xiaoting Wei
No Relationships to Disclose
 
Junjie Gu
No Relationships to Disclose
 
Chuanliang Cui
No Relationships to Disclose
 
Jiaxiang Wang
No Relationships to Disclose
 
Bin Lian
No Relationships to Disclose
 
Zhihong Chi
No Relationships to Disclose
 
Xinan Sheng
Speakers' Bureau - Astellas Pharma; Junshi Pharmaceuticals; MSD Oncology; Pfizer; RemeGen
 
Xuan Wang
No Relationships to Disclose
 
Bixia Tang
No Relationships to Disclose
 
Siming Li
No Relationships to Disclose
 
Xieqiao Yan
No Relationships to Disclose
 
Jun Guo
Consulting or Advisory Role - Bayer; MSD; Novartis; Oriengene; Pfizer; Roche; Shanghai Junshi BioSciences; Simcere